摘要
目的:通过观察以益气养心安神为立法组成的中药复方养心颗粒对近似不稳定型心绞痛家兔模型颈总动脉血小板源生长因子-BmRNA及血管内皮生长因子mRNA表达的影响,从分子生物学水平探讨其可能的作用机制,为临床应用提供理论依据。
方法:以球囊一次性损伤家兔颈动脉结合高脂饮食喂养,8周末后随机分为模型对照组、养心颗粒组,消心痛组和阿托伐他汀组,每组各7只,另取7只家兔为空白对照组,于10周末进行药物触发的方法复制成近似不稳定型心绞痛动物模型。运用体表彩色超声方法观察各组家兔颈总动脉内中膜厚度及血流变化情况:采用HE染色观察模型血管病理形态学变化;采用电镜观察超微结构变化:采用酶标法观察模型血脂成分含量变化;采用速率散射光比浊法测定血浆纤维蛋白原的水平;采用放免法检测血浆内皮素和一氧化氮含量的变化;采用RT-PCR法观察颈总动脉血小板源生长因子-BmRNA和血管内皮生长因子mRNA表达的变化。
结果:
1.根据体表超声测定,与空白对照组相比,各组在8周末时,均出现颈总动脉IMT明显增厚(P＜0.01),PI及RI显著增加(P＜0.05),而VS加快不明显,差异无统计学意义(P＞0.05)。10周末时,模型对照组IMT、PI、RI值继续增加,养心颗粒治疗组和消心痛治疗组的IMT、PI、RI值明显下降,与模型对照组相比,差异有统计学意义(P＜0.0 5),但不如阿托伐他汀组。
2.病理研究结果表明,除空白对照组外,各组均出现血管内皮损伤,血管内膜增厚,脂肪沉积明显,脂质斑块形成。各治疗组颈总动脉内皮细胞轻度减少,内膜轻度增厚,内膜下脂质沉积减少。
3.在第8周末时,除空白对照组外,各组TC、TG、LDL-C明显升高,HDL-C明显降低,差异有统计学意义(P＜0.01);第10周末时,模型对照组TG继续升高,与8周相比,差异有统计学意义(P＜0.01),TC、HDL-C、LDL-C均无明显变化(P＞0.05);养心颗粒组中的TG含量与8周末相比,无显著变化(P＞0.05),CHO和LDL-C明显降低,与8周末相比,差异有统计学意义(P＜0.05);阿托伐他汀组中TC、TG和LDL-C含量均有所降低,HDL-C升高,与8周末相比,差异有统计学意义(P＜0.05):消心痛治疗组各项指标均无明显影响(P＞0.05)。
4.与空白对照组相比,各组在8周末Fbg的含量明显升高,差异有统计学意义(P＜0.01);10周末,与模型对照组相比,各治疗组Fbg含量均有所降低,差异有统计学意义(P＜0.01);各治疗组间比较,养心颗粒疗效优于其他两组,差异有统计学意义(P＜0.05)。
5.与空白对照组相比,8周末各组血浆NO含量均显著降低,而血浆ET含量显著升高,差异有统计学意义(P＜0.01);10周末,与模型对照组比较,各治疗组血浆NO含量均有显著升高,血浆ET含量显著下降,差异有统计学意义(P＜0.05);各治疗组间相比较,消心痛组疗效优于另外两组,差异有统计学意义(P＜0.01),而养心颗粒与阿托伐他汀组相比,差异无统计学意义。
6.与模型对照组相比,各治疗组均可下调PDGF-B mRNA表达(P＜0.01),养心颗粒治疗组的PDGF-B mRNA表达显著低于消心痛和阿托伐他汀治疗组(P＜0.05);同时各治疗组均可上调VEGF mRNA的表达(P＜0.01),养心颗粒治疗组的PDGF-B mRNA表达显著高于另外两组,差异有统计学意义(P＜0.05)。
结论:以益气养心安神法组成的中药复方制剂养心颗粒对近似不稳定型心绞痛模型具有明确的防治作用,它可以下调PDGF-B mRNA表达,上调VEGF mRNA表达,其可能是通过调整人体阴阳平衡、改善血管内皮系统功能障碍、抑制血管内膜增生,从而改善模型血管的病理形态学的异常,减轻血管内膜增厚程度和斑块易损程度,起到防治不稳定型心绞痛的作用。
Objective:To observer the effects of recuperating-heart granule that it can to tonify Qi and stabilize the heart and calm the mind on rabbit model of similar unstable angina that the expression of arteria carotis communis PDGF-B mRNA and VEGF mRNA,to investigate its mechanism of action at level of molecular biology,to provide a reliable theoretic basis for this therapy.
Methods:Aortic wall injuries were introduced using an intravascular balloon in rabbits before they were fed on an a high fat diet for 8 weeks.At the end of week 8,rabbits were randomly divided into five groups.There are model control group; recuperating-heart granule group;Cedocard group;atorvastation group and blank group.There are 7 rabbits in every group.At the end of 10 weeks,to copy the model of similar unstable angina that used the method of Pharmacological triggering.to investigate the thickness and blood flow rate of arteria carotis communis by body surface chromatic color ultrasonography and to observe pathomorphism change of blood vessel by HE dyeing.to survey ultrastructure change by Electron microscope,and blood fat content change of model by enzyme linked immunosorbent assay;to determine fibrinogenic level by speed stray light turbidity method; detecting content change of blood serum NO and ET by immunology; observer the expressing change of arteria carotis communis PDGF-B mRNA and VEGF mRNA by RT-PCR.
Results:
1.According to the result of body surface ultrasonography,compare with the blank group,every group emerge that arteria carotis communis IMT obviously thicken(p＜0.01),PI and RI obviously addition(p＜0.05),but VS accelerate in nubibus.It was not considered statistically significant,at the end of 8 weeks.10 weeks later,model control group IMT PI RI continue increased,those compare with model control group,recuperating-heart granule group and Cedocard group IMT PI RI decreased obviously.It was considered statistically significant(p＜0.05),but the result in atorvastation group is better than them.
2.Effect of pathology research indicated,besides black control group,every group all emerge that vascular endothelial cell damaged,endangium thick,fatty deposition obviously,fatty substance plaque formed,each treatment group,arteria carotis communis endothelial cell decrease lightly,endomembrane thick lightly,fatty deposition decrease under endomembrane.
3.In the end of 8 weeks,TC TG LDL-C increase obviously and HDL-C decline obviously at each group except to blank control group.It was considered statistically significant(p＜0.01).TG at model group continue increased in ten weeks than 8 weeks,it was considered statistically significant(p＜0.01),TC、HDL-C、LDL-C has no any change(p＞0.05);TG have no significant change in Recuperating-heart granule group(p＞0.05),CHO and LDL-C obviously decline.it was considered statistically significant (p＜0.05).TC、TG and LDL-C decreased,HDL-C increased in atorvastation group,it was considered statistically significant (p＜0.05);the index has no any influence in Cedocard group.
4.Compare with blank group,Fbg obviously increase in each group at the end of 8 weeks,it was considered statistically significant (p＜0.01);AT the end of 10 weeks,Fbg decline in treatment group to compare with control group it was considered statistically significant(p＜0.01),compare with each other during treatment group,the function of Recuperating-heart granule is better than other group,itwas considered statistically significant(p＜0.05).
5.At the end of 8 weeks,to compare with black group,the contents of blood plasm NO all reduced obviously,while the contents of blood serum ET increase obviously in model group,it was considered statistically significant(p＜0.01).At the end of 10 weeks,to compare with model control group,the contents of blood plasm NO all increased obviously,the contents of blood plasm ET decreased obviously in each treatment group,it was considered statistically significant.Compare with each other during treatment group,the function of Cedocard group is better than other two group,it was considered statistically significant.While there is similar function between Recuperating-heart granule group and atorvastation group,it was not considered statistically significant
6.To compare with control group,the treatment group can down regulation expression of model PDGF-B mRNA.the express of Recuperating-heart granule group is lower than Cedocard group and atorvastation group(p＜0.05),at the same time,treatment group can up-regulation expression of VEGF mRNA(p＜0.01),the expression of PDGF-B mRNA in Recuperating-heart granule group significant higher than other two groups,it was considered statistically significant(p＜0.05).
Conclusion:Recuperating-heart granule which can tonify Qi and stabilize the heart and calm the mind on the model of similar unstable angina has protective effect definitely.It can improve system functional disturbance of vessel endothelium,down regulation the expression of PDGF-B mRNA,up-regulation expression of VEGF mRNA.It may be to regulate yin-yang balance of human body to improve the functional disturbance of blood vessel endothelial system,to restrain endangium hyperplasia,thus it can improve pathology form and ultrastructure abnormality of model blood vessel,it also reduce the thickness of endangium and extent of easy damage plaque.It can prevention and cure unstable angina.
引文
1 陈灏珠.实用内科学[M].第11版.北京:人民卫生出版社,2001.10.
2 刘德健,许宏大,陈建文.冠心病危险因素评估及临床意义[J].国际医药卫生导报,2007,(7):58-60.
3 刘永家,陈光宇,王琳.438例冠心病患者病因分析与防治对策[J]..成都中医药大学学报,2001,24(1):30.
4 文川,程伟.206例心绞痛患者问诊资料与中医辨证关系的探讨[J].湖北中医杂志,2002,24(10):3-4.
5 吴辉,于扬文,吴伟,等.116例冠心病患者中医证候及病因分析[J].江苏中医药,2004,25(10):30-31.
6 李芳,樊相军.胸痹诱发因素与辨证分型的调查分析[J].人民军医,2001,44(8):484-486.
7 李健,丁邦晗,张敏州,等.胸痹心痛的临床证型与部分冠心病危险因素的对比研究[J].中西医结合心脑血管病杂志,2005,3(2):97-99.
8 周荣斌,崔致贤.老年冠心病病人细胞免疫功能的研究[J].中国急救医学,2001,21(2):73-75.
9 唐关敏,江力勤,汪世君,等.冠心病病人外周血T淋巴细胞亚群及免疫球蛋白、补体变化的临床研究[J].中原医刊,2001,28(7):2-3.
10 沈自尹.肾的研究(续集).上海:上海科学技术出版社,1990:230-232.
11 贾跃胜,袁世宏,武改梅,等.胸痹心痛易患性体质初探[J].中医药研究,2001,17(4):5-6.
12 姜德友,邱海丽.胸痹心痛源流考[J].山东中医药大学学报,2007,31(4):319-321.
13 王中原,刘红,张永涛.中医药治疗冠心病心绞痛的研究概况[J].河南中医药学刊,2002,12(1):79.
14 林求诚.中医衰老指数与中老年年龄的初步分析[J].中西医结合杂志,1990(2):90.
15 叶壁珍.老年内科急证证候特点的分析研究[J].中医杂志,1990(5):20.
16 罗要文.胸痹心痛临床几个问题的探讨[J].四川中医,1988(12):8.
17 马晓昌,尹太英,陈可冀,等.冠心病中医辨证分型与冠状动脉造影所见相关性比较研究[J].中国中西医结合杂志,2001,21(4):654.
18 李祥国.冠状动脉痉挛心绞痛证治探讨[J].辽宁中医杂志,1984(1):17.
19 李芳,樊相军.胸痹诱发因素与辨证分型的调查分析[J].人民军医,2001,4(8):484-486.
20 樊永平.王氏保心丸防治冠心病的理论和实验研究[J].见:中医药大学博士研究生学位论文集.北京:北京中医药大学,1996.39-50.
21 王硕仁,赵明镜.冠心病心气虚证与左心室功能及心肌缺血相关性的临床研究[J].中国中西医结合杂志,1998,18(13):457-460.
22 黄修涛.冠心病“病证同一”与辨证思维模式[J].辽宁中医学院学报,2001,3(1):14-15.
23 李幼勋,王德华.胸痹的病因病机及其证治述略[J].实用中医内科杂志,2002,16(4):184-185.
24 黄榕康.浅谈胸痹证治[J].新中医,1994(7):59-60.
25 郝惠莉,王明亮.辨证分型治疗冠心病心绞痛 172例[J].浙江中医杂志,1996,31(1):13.
26 陈宏.试论心病从肾论治.国际中医心病学术会议论文集,1992.245.
27 杨开清,陈宏,黄衍寿.从肾论治冠心病之研究概况[J].新中医,1998(3):57.
28 陈东汉.脑血流图在冠心病中医辨证分型中的应用[J].福建中医药,1994,14(3):44-46.
29 孔繁立,兰若,尤松鑫,等.不稳定型心绞痛心肾阳虚证血浆性激素及自由基反应的变化[J].甘肃中医,1993,6(6):1.
30 李晓,丁书文,姜萍.心和颗粒剂保护冠心病患者血管内皮损伤的临床研究[J].中医杂志,2000,41(11):661-663.
31 袁丽萍.9 8例不同证型冠心病的超声心动图改变观察[J].云南中医学院学报,1999,22(2):2.
32 陈伯钩,张文清,张敏州.冠心病中医分型与心律失常及心功能关系分析[J].现代中西医结合杂志,2000,9(19):1857.
33 程小曲,刘茂甫,周淑意,等.冠心病及其辨证分型与超氧化物歧化酶过 氧化脂质等的关系[J].实用中西医结合杂志,1998,11(6):505.
34 孔繁立,兰若,尤松鑫,等.不稳定型心绞痛心肾阳虚证血浆性激素及自由基反应的变化[J].甘肃中医,1993,6(6):1.
35 张志玲,李惠林.冠心病血瘀证、痰浊证与血液流变学关系探讨[J].陕西中医,1998,19(8):361
36 何剑平.冠心病中医辨证与向脂蛋白关系的探析[J].辽宁中医杂志,1995,25(1):505.
37 贾宝善.冠心病患者血小板膜糖蛋白及血小板功能与中医证分型关系的研究[J].中西医结合杂志,1989,9(12):717.
38 刘志勇.补阳还五汤加味治疗冠心病心绞痛疗效评价[J].湖北中医学院学报,2000,2(3):28.
39 徐丽萍.四逆汤的药理研究进展[J].中国药事,2002,6(16):373.
40 高岚.四逆汤对左心室舒张功能的影响[J].现代中西医结合杂志,2000,9(2):112.
41 孙慧兰,吴伟康.四逆汤有效成分不同组合抗心肌缺血再灌注损伤的作用研究[J].中草药,2002,33(4):333.
42 秦鉴,吴伟康,李俊彪,等.四逆汤和消心痛单用或联用治疗冠心病心绞痛的比较研究[J].中国中医药科技,2001,8(1):6.
43 苏建文,吴伟康,林曙光,等.四逆汤对经皮冠状动脉成形术冠心病患者生活质量的随访报告[J].中国中西医结合杂志,1998,18(11):671.
44 曹忠良.参麦注射液治疗不稳定型心绞痛 20例[J].上海中医学杂志,2001,35(378):16.
45 李运伦.养心汤治疗冠心病心绞痛的临床研究[J].山东中医学院学报,1994,18(5):323.
46 王昕.复方丹参滴丸治疗不稳定型心绞痛疗效观察[J].解放军药学学报,2001,17(2):78.
47 冯陪芳.复方丹参滴丸对冠心病患者循环内皮细胞的内皮素基因表达的影响[J].中国中西医结合杂志,1999,19(5):286.
48 李宝华.血府逐瘀汤治疗不稳定型心绞痛 66例[J].陕西中医1999,20(12):559
49 高克俭.心绞痛从肝辨证施治的观察[J].天津中医,2000,19(5):7.
50 孙淑芝.养心疏肝汤治疗冠心病心绞痛 160 例[J].中级医刊,1994,29(2):56.
51 陈江斌,许家刑,江洪,等.三七总皂苷对冠心病患者过氧化脂质及纤维蛋白溶酶原激活物的影响[J].中国新药杂志,2000,9(11):781-782..
52 孙福忠.路路通注射液治疗冠心病、心绞痛的疗效观察[J].临床荟萃,1999,14(7):319-320.
53 陈际苏,赵兰坤,苏卫东.三七总皂苷注射液与复方丹参注射液治疗冠心病心绞痛的比较[J].中国新药与临床杂志,2000,19(6):458-460.
54 孔月琼,姚震,云美玲,等.丹参粉针治疗冠心病心绞痛患者的临床疗效及对血小板功能的影响[J].高血压杂志,2002,10(5):451-453.
55 齐华阁,刘建国,万国新,等.川芎嗪治疗冠心病不稳定型心绞痛的短期疗效观察[J].中国中西医结合杂志,1995,15(10):617.
56 付风昌.川芎素治疗冠心病心绞痛42例分析[J].实用中医内科杂志,2005,19(5):474.
57 李格,史载祥,贾海忠,等.大蒜素对不同中医证型不稳定性心绞痛的作用及与血脂和 GMP-140 的关系[J].中国中西医结合杂志,1998,18(4):208-211.
58 周群,汪晓云,蔺承艳,等.红花注射液对冠心病患者血小板、凝血及纤溶功能的影响[J].中国综合临床,2002,18(10):888-889.
59 寇咏梅,沈丽萍,张秀红.灯盏细辛与复方丹参注射液治疗冠心病心绞痛疗效对比[J].天津医药,2004,32(9):561-562.
60 任绍兰.复方丹参滴丸治疗不稳定型心绞痛 249例[J].河北中医,2002,24(7):496-497.
61 黄定香,陈建萍,于英奇.地奥心血康治疗胸痹(冠心病)的临床观察报告[J].成都中医学院学报,1990,13(4):26-30.
62 刘秀娟,王丽华.通心络胶囊治疗不稳定心绞痛临床疗效观察[J].中国民康医学,2006,18(8)701-702.
63 赵唯贤,徐毅.疏血通治疗冠心病心绞痛 35例.山东中医杂志,2002,21(6):345-346.
64 刘英华,王艳华,朱玉山.丹红注射液治疗不稳定心绞痛疗效观察[J].吉林医学.2007,28(9):1118-1119
65 高敏捷.银杏达莫治疗不稳定心绞痛的临床观察[J].中外医疗.2007,23:29.
66 王学福.参芎葡萄糖注射液治疗老年不稳定心绞痛40例临床观察[J].中国临床保健杂志.2006,9(4)376-377
67 李越凡.心可舒治疗不稳定心绞痛疗效观察.中国社区医师2006,8(15):64.
68 张常健.冠心宁注射液治疗老年不稳定心绞痛30例.医药导报.2006,25(10):1025-1026.
69 孙越冬.脉络宁注射液治疗不稳定心绞痛161例[J].中国中西医结合杂志,2002,12(7):428.
70 刁利红,严洁.针灸治疗冠心病心肌缺血临床研究概况[J].湖南中医学院学报,2004,24(4):59.
71 王兴.针刺治疗不稳定型心绞痛的临床疗效观察[J].针灸临床杂志,2000,16(3):15.
72 张学新.心痛膏治疗冠心病心绞痛173例临床观察[J].实用中西医结合杂志,1998,11(10):893.
73 刘 新.硝石雄黄散贴敷至阳穴防治冠心病心绞痛的临床研究[J].甘肃中医学院学报,2000,17(2):43-46.
74 薛 萍,王 仁.涌泉穴贴敷疗法对冠心病心绞痛的辅助作用[J].中医外治杂志,1996,3:29.
75 雷 燕.冠心病心绞痛中医外治法[J].中国临床医生,2000,28(10):19.
76 史爱武,钱士明.血压平滴鼻剂治疗不稳定性心绞痛临床研究[J]山东中医药大学学报,2000,24(5):341.
77 张建文,汪大鹏,熊小玲,等.复方丹参气雾剂治疗冠心绞痛的临床观察[J].湖北中医杂志,2005,27(1):15.
78 Chierchias.Current the rapeutic strategies in unstable angina[J].Eur Heart J,1999,1(supplN):2-6.
79 Theroux P,Lidon RM.Unstable angina:pathogensis,diagnosis and treat -ment[J]. CurrProblCardiol,1993,18:159-214.
80 Maggioni AP,schweiger C. Tavazzi Lon behalf of the EARISA Investigators. The diagnostic-the rapeutic processes in patients with unstable angina in Italy:results of the EARISA registry[J]. Eur Heart. 1,1998,19 (supplN):559.
81 Ronner E,Dykun Y,vanden Br and MJ BM,et al. Platelet glycoprote in Ⅱb/Ⅲa recept erantagoists. Anasset for treatment of unstable coronary Syndromes and coronary intervention[J]. Eur Heart J,1998,19:1608-1616.
82 PURSUIT Trial Investigators. Inhibition of platelet glycoprotein Ⅱb/Ⅲa with eptifiba tide in patients with acute coronary syndromes[J]. NEngl J Med,1998,339:436-443
83 Yusufs,Flather M,Pogue J,et,al. Variations between countries in invasive cardiac procedures and outcomes inpatients with suspected unstable angunaor myocardial infarction without initial ST elevation[J]. Lancet,1998, 352:507-514.
84 Califf RM when I have acute coronary syndrome,treat megingerly[J]. Eur Heart J, 1999,20:20-25
85 陈灏珠, 何梅先, 魏盟, 葛均波. 实用心脏病学上海科学技术出版社2007,9: 891.
86 Armstrong PW,Fu Y,Chang WC,et,al. Acute coronary syndrome in the GUSTO-Ⅱ btrial:prognostic insights and impact of recurrent ischemia. The GUSTO- Ⅱb lnvestigators[J]. Circulation, 1998,98:1860-1868.
8 7 Cannon CP,McCabe CH, Stone PH,et al. The electro cardio gram predicts on eyearact come of patients with unstable angina and non-Q wave myocardial infarction:results of the TIMIⅢRegistey ECG Ancillary study. Thrombolysis in Myocardial Ischemia[J]. Jam CallCardiol,1997, 30(1): 133-140.
8 8 Hamm CW. Gddmann BU,Heeschen C,et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac tropon in Tortroponin I[J]. NEngl J Med,1997,337:1648-1653.
89 The TIMIⅢB Investigators. Effects of tissue plasminogen activator and acomparison of early invasive and conservative stratigiesin unstale angina and non-Q wave myocardial infanction. Resultsof the TIMIⅢB Trail[J]. Circulation,1994,89:1545-1556.
90 Braunwald E.Management of unstable angina bases on considerations of aetiolog[J].Heart,1999,82(suppl 1):15-17.
91 Rebuzzi AG,Quaranta L,Liuzzo G,et al.Incremental prognostic value of serum levels of tropinin T and Crealtive protein on admission inpatients with unstable argina pectoris[J].Am J Cardiol,1998,82:715-719.
92 Biasucci LM,Liuzzo G,Grillo RL,et al.Elevated levels of Creactive protein at discharge inpatient with unstable angina apectoris recurrent instability[J].Circulation,1999,99:2079-2084.
93 Kaski JC.Chester MR,Chen L,et al.Rapid angiographic progression of coronary artery disease inparionts with angina pectoris:the role of complex srenosis morphology[J].Circulation,1995,92:2058.
94 马 今,吴学思.不稳定型心绞痛病生理研究进展[J].心肺血管病杂志,1999,(2):36-38.
95 张淑华,于俊民,曹滨冬,等.不稳定型心绞痛病人内皮细胞损伤的研究[J]..哈尔滨医科大学学报,2000,34(4):277-278.
96 金 露.不稳定型心绞痛患者内皮及血小板活化功能检测的临床意义(摘要)[J].中国循环杂志,2000,15(1):18.
97 沈潞华.不稳定型心绞痛的发病机理、临床特点及危险分层[J].北京医学,2001,23(3):175-176.
98 蒋延波,杨俊华.急性冠状动脉综合征的血管内超声特征[J].中华心血管病杂志,2002,30(6):356-359.
99 吴宗贵.重视对急性冠脉综合征的研究[J].第二军医大学学报,2001,22(2):103-104
100 Mann JM,Davies MJ.Vulnerable plaque-relation of characteristrcs to degree of stenosis in human coronary arte[J].Circulation,1996,94:928-931.
101 张嘉莹,张菲斐,翟亚萍,等.不稳定型心绞痛炎性细胞因子水平与冠状动脉狭窄的对比分析[J].中国循环杂志,2000,15(4):81-82.
102 Jamieson GA.Pathophy siology of plate let thromb in receptors[J]Thromb Haemost,1997,78:242-246.
103 路亚枫,秦明照.不稳定型心绞痛患者血浆TE、TEPI含量和活性的变化[J].基础医学与临床,2002,22(2):175-176.
104 张菲斐,邵建华,朱兴雷,等.不稳定型心绞痛患者活化血小板表达细胞分化抗原40配体及其与可溶性黏附分子水平的关系[J].中国循环杂志,2002,17(1):20-22.
105 王燕妮,赵永辉,祝家庆,等.血小板膜糖蛋白基因多态性在不稳定型心绞痛发生机制中作用的探讨[J].中国循环杂志,2002,17(2):124-126.
106 冯惠平,冯惠清,吴坎金,等.睡眠呼吸暂停综合征血栓前状态的研究进展[J].国外医学呼吸分册,2002,22(1):52-54.
107 夏大胜,刘书坤,高陆,等.不稳定型心绞痛患者心理社会因素与血小板聚集功能关系的研究[J].天津医药,2001,29(3):131133.
108 赵季红,侯允天,张利华.冠心病与炎症的关系及C反应蛋白新的临床意义[J].心脏杂志,2001,13(5):309-401.
109 Gurfinkel E,Bozovich G.Chlamy diapneumoniae:inflammation and instability of the ather osclerotic plaque[J]Athe-rosclerosis,1998,140(Suppl1):31-35.
110 崔翰斌,崔长琮.肺炎衣原体感染致动脉粥样硬化机制的研究进展[J].中华内科杂志,2002,41(4):281-283.
111 葛长江,郭新贵.血清肺炎衣原体抗体滴度水平对不稳定型心绞痛及其预后的临床预测价值[J].中国病理生理杂志,2002,18(8):998.
112 Zaman AG,Helft G,Worthley SG,et al.The role of plaque rupture and thrombosis in coronary disease[J].Atherosclerosis,2000,149(2):251-256.
113 Liao JK.Endo the lium and acute coronary syndromes[J].ClinChem,1998,44(8):1799- 1808.
114 Keshavamurthy CB,Kane GR,Magdum AP,et al.Serum fibrinoden and Creactive protein levels predict major adverse cardiac events in unstable angina[J].Inadian Heart J,2000,52(1):3639.
115 Ridker PM.Creactive protein:A simple test to help predict risk of heart attack and stroke[J].Circulation,2003,108(12):81-85.
116 Danesh J,Wheeler JG,Hirshfield GM,et al.Creactive protein and other circulatory markers of inflammation in the prediction of coronary heart disease[J].NEnglJMed,2004,350:1387- 1397
117 李 华.血浆纤维蛋白原与急性冠脉综合征的相关性研究[J].医学信息,2006,19(5):367-368.
118 Armstrong E J,Morrow D A,Sabatine M S.Inflammatory biomarkers in acute coronary syndromes:Part Ⅰ:introduction and cytokines[J].Circulation,2006,113(6):e72-e75.
119 Ridker PM,Hennekens CH,Buring JE,et al.Creactive protein and other markers of inflammation in the prediction of cardio vascular disease in women[J].NEng J Meal,2000,342(12):836-843.
120 Bayes-Genis A,Conover CA,Overgaard MT,et al.Pregnancy-Associated plasma protein Aasa marker of acute coronary syndromes[J].NEngl JMed,2001,345(14):1022- 1029.
121 Lund J,Qin Q P,Ilva T,et aI.Circulating pregnancy-associated plasma protein-A predicts outcome inpatients with acute coronary syndrome but no troponin I elevation[J].Circulation,2003,108(16):1924-1926.
122 Inokubo Y,Hanada H,Ishizaka H,et al.Plasma levels of matrix metallo proteinase-9 and tissue inhibitor of metallo protein as e-lareincreased in the coronary circulation inpatients with acute corinary syndrome[J].Am Heart J,2001,141(2):211-217.
123 Blankenberg S,Rupprecht HJ,Poirier O,et al.Plasma concentrations and genetic variation of matrix metallo proteinase-9 and prog-nosis of patients with cardio vascular disease[J].Circulation,2003,107(12):1579-1585.
124 Baldus S,Heeschen C,Meinertz T,et al.Myeloper oxidaseserum levels predict risk in patients with acute coronary syndromes[J].Circulation,2003,108(12):1440- 1445.
125 Kanda T,Takahashi T.Interleukin-6 and cardio vascular diseases[J]. JpnHeart J,2004,45(2): 183-193.
126 Delemos J A, Morrow D A,Sabatine M S,et al,Association between plama levels of monocyte chemo attract ant protein-land long-term clinical outcomes inpatients with acute coronary syndromes[J]. Circulation, 2003,107(5):690-695.
127 Bossowska A,Kiersnowska-Rogowska B,Bossowski A,et al. Assessment of serum levels of adhesion molecules (sICAM-1 ,sV-CAM-1 ,sE-selectin) instable and unstable angina and acute myocardial infarction[J]. Przegl Lek, 2003, 60(7):445- 450.
128 Ridker PM,Buring JE,Rifai N. Soluble P-selection and the risk of future cardio vascular events[J]. Circulation,200 1,103(4):49 1-495.
129 Varo N,deLemos J A,Libby P,et al. Soluble CD40L:risk prediction after acute coronary syndromes[J]. Circulation,2003,108(9):1049-1052.
130 Heeschen C,Dimmeler S,Fichtlscherer S,et al. Prognostic value of placental growth factor inpatients with acute chestpain[J]. JAMA,2004, 291(4):43 5-441.
131 Zhu Y,Hojo Y,Ikeda U,et al. Production of hepatocyte growth factor during acute myocardial in farction[J]. Heart,2000,83(4):450-455.
132 Ardissino D, Merlini PA, Bauer KA,et al. Thrombp genic potential of human coronary other osclerotic plaques[J]. Blood, 2001, 98(9):2726-2729.
133 Ridker PM, Cushman M,Stampfer MJ,et al. Inflammation, aspirin,and the risk of cardio vascular disease in apparently healthy men[J]. NEngl J Med,1997,336(14):973-979.
134 Ehara S,Ueda M,Naruko T,et al. Elevated levels of oxidized low density lipo protein show a positive relationship with the severity of acute cornory syndromes[J]. Circulation,2001,103(15):1955-1960.
135 Varo N,deLemos J A,Libby P,et al. Soluble CD40L:risk prediction after acute coronary syndromes[J]. Circulation, 2003, 108(9); 1049-1052.
136 Kazlauskas A. A new member of an old family[J]. Nat Cell Biol 2000, 2(5)E78-E79.
137 Doolitle RF, Hunkapiller MW, Hood LE, et al. Simian sarcoma virus nco-ene,vsis, is derived from the gene(or genes)encoding a platelet derived growth factor. Science[J]. 1983, 221: 275-277.
138 Waterfield MD, Scrace GT, Whitle N,et al. Platelet derived growth factor is structurally related to the putative transforming protein p28-sis of Simian sarcoma virus, Nature[J]. 1983, 304: 35-39.
139 Raines EW, Bowen-Pope DF, Ross R. Platelet derived growth factor. In: Spom MB, Roberts AB, eds. Handbook of Experimental Pharmacology: Peptide Growth Factors and Their Receptors Heidelberg:Springer verlag[J],1990: 173-262.
140 Heldin C H, Wcstennark B. Physiol Rev[J], 1999, 79(4): 1283-1316.
141 Heldin C H, Ostman A, Ronnstrand L[J]. Biochem Biopys; Acta,1998, 1378(1): F79-113.
142 Ihling C. Pathomorphology of aoronary ather oscleresis[J]. Herz, 1998, 23:69-77.
143 Morishita R. Euison KE,et al. Evdence for direct local effect of angiotension in vascaular hypertrophy invivogene transfer of angioteusion converting enzyme[J]. J clininvest, 1994,94:978-984.
144 Cereck B,et al. Induction of insulin like growth factor I messenger RNA in rat aorta after ballon denudation. Circ Res,2000,66: 1755-1761.
145 Brien ER,Garvin MR, Dev R,et al. Angio genesis in human coronary other osclerotic plaques[J]. Am J Pathol, 1994,145:883-894.
146 Netifeld G, Gohen T,Gengrinovitch S,et al. Vascular endo the-lial growth factor (VEGF)and its receptors. FASEB J, 1999,13 :9-22.
147 Vale PR. Losordo DW,Milliken CE, et al. Images in cardio vascular medicine percutaneous myocardial gene transfer of phVEGF- 2. Circulation, 1999,100:2462- 2463.
148 Achen MG,Stacker SA, The Vascular endothelial growth factor family: proteins which guide the development of the vasculature. Int J Exp Path, 1998,79:255- 265.
149 Hao Z,Franklin B.How do cells sense oxygen Science,2001,292:449-451.
150 Kalka C,Masuda H,Takahashi T,et al.Transplantation of exvivo expanded endothelial progenitor cells for therapeutic neovascularization.Proc Natl Acad Sci USA,2000,97:3422 -3427.
151 黄庆愿,高钰琪,史景泉,等.缺氧大鼠心肌毛细血管密度与VEGF变化的研究[J].第二军医大学学报,2001,23:633-636.
152 刘闺男,腾雅轩,王恩华.Ang-1(2-10)对大鼠急性心肌梗死后VEGF和bFGF表达及血管形成的影响[J].中国组织化学与细胞化学杂志,2002,11:153-158.
153 黄震华.钙通道拮抗剂在各种心绞痛治疗中的评价[J].综合临床医学,1991,68:1368.
154 Husain S.Andrens NP,Mulcahy D,et al.Aspirin improve sen-do the lialdys fuction in other osclerosis.Circulatic,n,1998,97:716
155 The PRISM study in vestigators Acomparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.NEngl J Med,1998,338:1498.
156 邱朝辉.血小板GP Ⅱb/Ⅲa受体拮抗剂治疗急性冠脉综合征的研究进展[J].国外医学·心血管疾病分册,2001,28(1):9.
157 Schusshein AE,Fuster V.Throbosis,antithrombotic agents,and the antithrombotic approach in cardic diseasc.Progress in cardio vascular Disease,1997,40:213.
158 Haire WD.Pharmacology of fibrindysis.Chest,1992,101:915.
159 陈纪林,徐文枢,陈在嘉.不稳定心血管溶栓治疗现状的评述[J].中华心血管杂志,1997,25(6):409
160 Romeo F,Rosano GMC Martuscell E,et al.Effectiveness of prolonged low closer ecombin ant tissue-type plasmigen activator for refractory unstable angina TACC,1995,25(60):1295
161 Constantinides P,Chakravarti RN.Rabbit arterial thrombosis production by systemic procedures.Arch Pathol,1961,72:197-208
162 Prescott M F,McBride C H,Hasler Rapacz J,et al.Development of complex atherosclerotic lesions in pigs with inherited hyper LDL cholesterolemia bearing mutant alleles for apolipo protein B.Am J Pathol 1991;139(1):139-147.
163 Rekhter MD,shah N,Simari RD,et al.Animal model thatmimics atherosclerotic plaque rupture.Circ Res 1998;83(7):705 -713.
164 Abela GS,Picon PD,Friedl SE,et al.Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model.Circulation 1995;91(3):776-784.
165 文 川,徐浩,黄启福,等.活血中药对ApoE基因缺陷小鼠血脂及动脉粥样斑块炎症反应的影响[J].中国中西医结合杂志 2005:25(4):345-349.
166 刘恒方,黄晓松,刘尊敬.颈动脉狭窄动物模型制作的研究进展[J].国际神经病学神经外科学杂志.2006,33(1):62-65
167 Holm J,Hansson GK.Cellular and immunologic features of carotidartery disease in man and experimental animal models.Eur JVasc Surg,1990,4(1):49-55.
168 陈建平,顾卫平,卢尔滨等.冠心病患者情绪障碍调查[J].中国心理卫生杂志.1997:11(3):114-116.
169 王旭梅,霍 彬,白 雪等.冠心病和惊恐障碍患者的临床对照研究[J].中国临床康复,2004:8(21):4157-4159.
170 黄震华,杨菊贤.心理因素与心血管事件[J].国外医学心血管疾病分册,1997,24(3):22.
171 高卫真,康毅,焦建杰,等黄茂普阿霉素心肌损伤的保护作用[J].研究中医药学刊,2003,21:2011-2013.
172 卢成志,李玉光,黄民.注射液对心肌细胞缺氧缺糖复氧复糖损伤保护作用的实验研究[J].实用中西医结合杂志,1998,11:10-12.173.
173 李树青,贺宏.黄芪对冠心病心绞痛病人血清和的作用[J].中西医结合心脑血管病杂志,2003,1:23-24
174 何正光,徐晓玉.黄芪对血管保护作用的药理研究进展[J].中国药房,2005,16:1589-1590.
175 郑熙龙,严幼芹.人参茎叶皂贰对家兔慢性高脂血的脂质调节及抗过氧化脂质作用[J].中国药理学通报.1991,7(2):110-113.
176 沈阳军区总医院药局.复方当归注射液对人体血液纤维蛋白溶解活性的影响[J].辽宁医药,1978,(5):6.
177 黄力强.川芎对心脑血管疾病活血化瘀药理作用的探讨[J].辽宁中医杂志,2000,27(10):469.
178 沈雅琴,张明发.半夏的镇痛、抗溃疡和抗血栓作用的形成[J].中国生化药物杂志,1998,19(3):141.
179 杨学东.天然产物研究与开发,2000,12(5):58.
180 陈一,钟正贤,黄凤娇,等.中药肉桂的药理研究(第一报):对血液和心血管系统的影响[J].中药通报,1981,(5):32.
181 高学敏,钟赣生.临床中药学[M].河北科学技术出版社,2006:444-965.
182 陈兴坚,余传林,刘菊芳酸枣仁总皂苷对培养大鼠心肌细胞的保护作用[J].中国药理学报,1990:11(2):153.
183 王锦鸿,陈仁寿.临床实用中药辞典[M].金盾出版社,2003:12-826
184 Shah PK.Plaque disruption and thrombosis:potential role of inflame-mation and infection[J].Cardiol Rev,,2000,20(8):31-39.
185 李仪奎,等,主编,中药药理学,第一版,北京中国中医药出版社,1992:202.
186 Paragh G.Treatment possibility of hyperchol seterolaemia associatec with hypertrigly ceridaemia,ActaBio;Hung.1997.48(3):359-367.
187 牛俐,邓子兵.半夏白术天麻汤新用[J].中国民间疗法,2002,10(11):55-56.
188 吴树勋,等.酸枣油及酸枣浸膏降血脂和抗血小板聚集作用的实验研究[J].中国中药杂志,1991,16(7):435.
189 曲淑岩,等.刺人参的抗炎作用[J].中草药,1986.17(7):25.
190 李淑芳,韩国强.酸枣仁的抗炎作用[J].贵阳医学院学报,1994:19(4):336-338.
191 Bond MG,Money D,Keele J,et al New perspectives for clinical evaluation of atherosclerosis[J].Drug Dev Res,1985,6;127-134.
192 SALONEN JT,SALONER R.Ultrasound B mode imaging in observational studies of ather osclerosis progression[J].Circulation,1993,87(2):56-65.
193 陈忠,马根山,黄 峻,等.早发冠心病病人颈动脉内膜中膜厚度特点及其预测价值[J].中国动脉硬化杂志,2004,12(1):81-83.
194罗心平,施海明,朱 军,等.血管内超声评价内皮依赖性血管舒张功能异常[J].中国超声医学杂志,1998:14(7):10-13.
195 Meade TW,North WRS,Chakrabarti R,et al.Haemostatic function and cardiovascular death:early results of aprospective study.Lancet,1980,1:1050-1054.
196 Wilhelmsen L,Svardsudd K,Korsan Bengsten K,et al.Fibrinogenasa risk factory for stroke and myocardial infarction.NEng I J Med,1984,31:501 -505.
197 Lowe GD O,Fowkes FG R,Dawes J,et al.Blood viscosity,fibrinogen,and activation of coagulation and leukocytes in peripheral arterial is ease and the normal population in the Edinburgh hartery study.Circulation,1993,87,1915-1920.
198 Loukas M,Dabrowski M,Wagner I et al.Fibrinogen and smooth muscle cell detection in atherosclerotic plaques from stable and unstable angina animmunohisto chemical study.Med Sci Monit,2002,8:144-148.
199 Smith EB,Keen GA,Grant A,et al.Fate of fibrinogen in human arteriosclerosis,1990,10:263-275.
200 Humphrise SE.Genetic regulation of fibrinogen.Ann NYA cad Sci,1995,748:461-471.
201 Smith EB,Thompson WD.Fibrinasa factor in atherogenesis.Thromb Res,1994,73:19
202 陈 伟,程 洁,王根发,等.缺血性卒中患者血浆纤维蛋白原和进动脉斑块关系的研究[J].临床内科杂志,2003,20(8):424-425.
203 Ernst E,Resch KL.Fibrinogcnasa cardiovascular risk factor:ameta analysis and review of the literature.Ann Int Med,1993,118:956-963.
204 刘影哲,周亚滨,韩佳瑞,等.养心汤对不稳定型家兔血浆前列腺素及主动脉及心肌超微结构的影响[J].中国中医药科技,2006,13(1):24-25.
205 刘影哲,周亚滨,韩佳瑞,潘祥宾.养心汤对家兔不稳定刑心绞痛模刑血浆TXB2含量及颈总动脉内中膜厚度的影响[J].中西医结合心脑血管病杂志,2006,12(4):1067-1068.
206 贾杰芳,马庆海,杨文东.急性心肌梗死患者溶栓前后血清VEGF水平的变化及临床意义[J].细胞与分子免疫学杂志,2002,18(5)503-504.
207 刘影哲.养心颗粒治疗冠心病心律失常及不稳定型心绞痛的实验研究.黑龙江中医药大学博士学位论文.2007.